This study assessed plazomicin’s in-vitro efficacy against colistin-resistant Enterobacteriaceae, including mcr-1 producers. It concluded that plazomicin showed superior susceptibility compared to other aminoglycosides across resistance types.
A 70-year-old man with long-standing diabetes, HTN, CAD, and latent TB presented with IgA nephropathy. Treated with corticosteroids, isoniazid, and diabetes care, he had reduced proteinuria, improved albumin, stable renal function, and no active TB